Health Trials

About this trial

The goal of this study (interventional clinical research not involving a health product) is to assess the prevalence of subclinical coronary atherosclerosis diagnosed by coronary CT angiography in heart failure patients in primary prevention, across different levels of cardiovascular risk defined by coronary artery calcium (CAC) score percentiles (based on data from the MESA study): low risk (≤25th percentile for age, sex, and ethnicity), intermediate risk (25th \< CAC ≤ 75th percentile), and high risk (\>75th percentile). The Patients will attend an on-site visit at inclusion (and must undergo a coronary CT angiography within 6 months following this visit), will be contacted by phone at 1 year and 2 years, and will return for an on-site visit at 30 months.

Eligibility criteria

Qualifiers

Person willing to sign the study consent form

Person affiliated with a current social security scheme

Person with a definite diagnosis of Familial Hypercholesterolemia, defined by a Dutch Lipid Clinic Network (DLCN) clinical-biological score > 8 and/or an identified causal mutation in the LDL receptor (LDLR) gene, apolipoprotein B100 gene, PCSK9 gene, or apolipoprotein E gene

Male aged 40 years or older, or female aged 50 years or older

Disqualifiers

Subject with a technical contraindication for coronary CT scan: patient diameter > 70 cm and/or weight > 250 kg

Patient with a history of atherosclerotic cardiovascular event (myocardial infarction, ischemic heart disease, coronary revascularization, ischemic stroke, carotid endarterectomy, lower limb arterial revascularization)

Patient allergic to iodinated contrast agents

Severe renal insufficiency: estimated glomerular filtration rate (eGFR) according to the CKD-EPI formula ≤ 30 ml/min

Trial design

Treatments tested in this trial

  • Coronary CT scan with CAC score measurement

Treatment groups

600 Participants
are divided into 1 treatment group

Locations

9
CHU Dijon Bourgogne Dijon France
CHRU Lille Lille France
Hospices Civils de Lyon Lyon France
Hôpital de la Conception, AP-HM Marseille France

Sponsors and collaborators

Nantes University Hospital

Lead sponsor

France 2030 program

Collaborator

European Union

Collaborator

Source ClinicalTrials.gov